Evidence map›Paper›PMID 38499691›Full record

ReviewRadiologie (Heidelberg, Germany)2024

[Structured screening for sporadic breast cancer].

Stefanie Weigel, Alexander Katalinic

Abstract readReview
PubMed Publisher
In one paragraph

Review in Radiologie (Heidelberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Stefanie WeigelKlinik für Radiologie und Referenzzentrum Mammographie Münster, Universität Münster und Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Deutschland. weigels@uni-muenster.de.
Alexander KatalinicInstitut für Sozialmedizin und Epidemiologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck und Universität zu Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of secondary prevention of breast cancer is to detect the disease at the earliest curable stage and thus to reduce breast cancer-specific mortality. To this end, the nationwide population-based mammography screening program (MSP) was set up in Germany in 2005 in addition to an interdisciplinary prevention project for high-risk groups.

objectiveOverview of the current state of the MSP, the upcoming age expansion, and potential further developments. MATERIAL AND

methodsNarrative review article with topic-guided literature and data search.

resultsApproximately 50% of the 70,500 new cases of breast cancer that occur each year are related to the age group of the MSP. 10 years after introduction of the MSP, the incidence of advanced breast cancer stages and breast cancer-related mortality of the screening target group have steadily decreased by about one quarter, while no relevant trends were seen in the neighboring age groups at the population level.

conclusionThe MSP has effectively contributed to a reduction of breast cancer mortality. With the expansion of the age groups to 45-75 years, more women have access to structured, quality assured screening. With the use of advanced stratifications and diagnostics as well as artificial intelligence, the MSP could be further optimized.

Indexed as

Breast NeoplasmsMammographyAdultAgedEarly Detection of CancerFemaleGermanyHumansMass ScreeningMiddle AgedAdvanced tumor stagesAge expansionBreast cancerDigital breast tomosynthesisMammography screening

Identifiers

PMID38499691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.